

Applicant : Nai-Kong CHEUNG Atty. Dkt. # : 639-C-PCT-US
USSN : 10/565,484 Art Unit : 1623
Filed : January 17, 2006 Date of Office Action: June 16, 2009
Examiner : Eric Olson Date of Response : September 9, 2009
Page : 3

AMENDMENT TO THE CLAIMS

This listing of claims will replace all prior listings or versions of claims in this application.

1-13. (Canceled)

14. (Previously Presented) A composition comprising:

(a) a composition comprising an antibody that binds to a cancer cell, and at least one pharmaceutically acceptable carrier, wherein the cancer is selected from the group consisting of neuroblastoma, melanoma, non-Hodgkin's lymphoma, breast cancer, Epstein-Barr related lymphoma, Hodgkin's lymphoma, and epidermoid carcinoma; and

(b) an orally administered composition comprising at least one pharmaceutically acceptable carrier and a soluble β -glucan in an amount effective to enhance the antitumor effect of said antibody, wherein the β -glucan comprises a β -1,3 backbone and at least one β -1,3 side chain of two or more glucose units linked to the backbone by a β -1,6 glycosidic bonds.

15. (Previously Presented) The composition of claim 14, wherein the β -glucan is isolated from yeast.

16. (Previously Presented) The composition of claim 14, wherein the β -glucan is isolated from *Saccharomyces Cerevisiae*.

Applicant : Nai-Kong CHEUNG Atty. Dkt. # : 639-C-PCT-US
USSN : 10/565,484 Art Unit : 1623
Filed : January 17, 2006 Date of Office Action: June 16, 2009
Examiner : Eric Olson Date of Response : September 9, 2009
Page : 4

17. (Currently Amended) The composition of claim 14, wherein the β -glucan has a molecular weight from about 10 kDa to about 350 kDa and is capable of inducing cytokines.

18. (Canceled)

19. (Previously Presented) The composition of claim 14, wherein the antibody is a monoclonal antibody or a complement-activating antibody.

20. (Previously Presented) The composition of claim 14, wherein the antibody binds to a cancer cell expressing an antigen selected from the group consisting of CD20, HER2, EGFR, GD2, and GD3.

21. (Previously Presented) The composition of claim 14, wherein the antibody is further capable of activating an antibody dependent cell-mediated cytotoxicity response.

22. (Previously Presented) A composition comprising:

- (a) a composition comprising an antibody that binds to a cancer cell, and at least one pharmaceutically acceptable carrier, wherein the antibody binds to a cancer cell expressing an antigen selected from the group consisting of CD20, HER2, EGFR, GD2, and GD3; and
- (b) an orally administered composition comprising at least one pharmaceutically acceptable carrier and a soluble β -glucan in an amount effective to enhance the antitumor effect of said antibody, wherein the β -glucan comprises a

Applicant : Nai-Kong CHEUNG Atty. Dkt. # : 639-C-PCT-US
USSN : 10/565,484 Art Unit : 1623
Filed : January 17, 2006 Date of Office Action: June 16, 2009
Examiner : Eric Olson Date of Response : September 9, 2009
Page : 5

β -1,3 backbone and at least one β -1,3 side chain of two or more glucose units linked to the backbone by a β -1,6 glycosidic bond.

23. (Previously Presented) The composition of claim 22, wherein the β -glucan is isolated from yeast.
24. (Previously Presented) The composition of claim 22, wherein the β -glucan is isolated from *Saccharomyces Cerevisiae*.
25. (Currently Amended) The composition of claim 22, wherein the β -glucan has a molecular weight from about 10 kDa to about 350 kDa and is capable of inducing cytokines.
26. (Canceled)
27. (Previously Presented) The composition of claim 22, wherein the antibody is a monoclonal antibody or a complement-activating antibody.
28. (Previously Presented) The composition of claim 22, wherein the cancer cell is selected from the group consisting of neuroblastoma, melanoma, non-Hodgkin's lymphoma, breast cancer, Epstein-Barr related lymphoma, Hodgkin's lymphoma, and epidermoid carcinoma.
29. (Previously Presented) The composition of claim 22, wherein the antibody is further capable of activating an antibody dependent cell-mediated cytotoxicity response.